

# Author Index Volume 5 (2016)

The issue number is given in front of the pagination

- Agrawal, S., see Berggren, K.L. (1) 53–63  
Andelic, N., see van Walsem, M.R. (3) 261–270  
Anderson, K.E., S. Eberly, M. Groves, E. Kayson, K. Marder, A.B. Young, I. Shoulson and PHAROS Investigators, Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease (4) 389–394  
Andrews, S.C., see Philpott, A.L. (2) 175–183  
Andrzejewski, K.L., A.V. Dowling, D. Stamler, T.J. Felong, D.A. Harris, C. Wong, H. Cai, R. Reilmann, M.A. Little, J.T. Gwin, K.M. Biglan and E.R. Dorsey, Wearable Sensors in Huntington Disease: A Pilot Study (2) 199–206  
Aronin, N., see Keeler, A.M. (3) 239–248  
Aronin, N., see Liu, W. (1) 33–38  
Aronin, N., see Vodicka, P. (2) 163–174  
Aronin, N., see Vodicka, P. (3) 249–260  
  
Baake, V., E.P. Hart, R. Bos and R.A.C. Roos, Participants at the Leiden Site of the REGISTRY Study: A Demographic Approach (1) 83–90  
Bates, G.P., see Osmand, A.P. (4) 343–346  
Berggren, K.L., Z. Lu, J.A. Fox, M. Dudenhoefter, S. Agrawal and J.H. Fox  
Bichell, T.J., see Osmand, A.P. (4) 343–346  
Biglan, K.M., see Andrzejewski, K.L. (2) 199–206  
Billes, V., T. Kovács, B. Hotzi, A. Manzáger, K. Tagscherer, M. Komlós, A. Tarnóci, Z. Pádár, A. Erdős, A. Bjelik, A. Legradi, K. Gulya, B. Gulyás and T. Vellai, AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease (2) 133–147  
Bjelik, A., see Billes, V. (2) 133–147  
Bos, R., see Baake, V. (1) 83–90  
Bouwens, J.A., E. van Duijn, C.M. Cobbaert, R.A.C. Roos, R.C. van der Mast and E.J. Giltay, Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease (4) 369–377  
Bowman, A.B., see Osmand, A.P. (4) 343–346  
  
Braisch, U., S. Martinez-Horta, M. MacDonald and M. Orth, Important but not Enough – Information about HD Related Topics and Peer and Professional Support for Young Adults from HD Families (4) 379–387  
Brooks, S.P., see Yhnell, E. (2) 149–161  
Byrne, L.M. and E.J. Wild, Cerebrospinal Fluid Biomarkers for Huntington's Disease (1) 1–13  
  
Cai, H., see Andrzejewski, K.L. (2) 199–206  
Cepeda, C., see Chen, J.Y. (1) 65–81  
Chase, K., see Keeler, A.M. (3) 239–248  
Chase, K., see Vodicka, P. (2) 163–174  
Chase, K., see Vodicka, P. (3) 249–260  
Chase, K.O., see Liu, W. (1) 33–38  
Chen, J.Y., C. Tran, L. Hwang, G. Deng, M.E. Jung, K.F. Faull, M.S. Levine and C. Cepeda, Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism (1) 65–81  
Chopra, V., L. Quinti, P. Khanna, P. Paganetti, R. Kuhn, A.B. Young, A.G. Kazantsev and S. Hersch, LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease (4) 347–355  
Churchyard, A., see Philpott, A.L. (2) 175–183  
Cobbaert, C.M., see Bouwens, J.A. (4) 369–377  
Corey-Bloom, J., S. Gluhm, A. Herndon, A.S. Haque, S. Park and P.E. Gilbert, Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease (1) 91–96  
Culver, B.P., J. DeClercq, I. Dolgalev, M.S. Yu, B. Ma, A. Heguy and N. Tanese, Huntington's Disease Protein Huntingtin Associates with its own mRNA (1) 39–51  
  
D'Souza, G.X. and H.J. Waldvogel, Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease (4) 333–342

- Danielson, E., see Keeler, A.M. (3) 239–248  
 De Soriano, I., see Downing, N.R. (4) 357–368  
 DeClercq, J., see Culver, B.P. (1) 39–51  
 Deng, G., see Chen, J.Y. (1) 65–81  
 DiFiglia, M., see Keeler, A.M. (3) 239–248  
 DiFiglia, M., see Liu, W. (1) 33–38  
 DiFiglia, M., see Vodicka, P. (2) 163–174  
 DiFiglia, M., see Vodicka, P. (3) 249–260  
 Dolgalev, I., see Culver, B.P. (1) 39–51  
 Dorsey, E.R., see Andrzejewski, K.L. (2) 199–206  
 Dowling, A.V., see Andrzejewski, K.L. (2) 199–206  
 Downing, N.R., S. Lourens, I. De Soriano, J.D. Long and J.S. Paulsen for the PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD (4) 357–368  
 Dudenhoefter, M., see Berggren, K.L. (1) 53–63  
 Dunnett, S.B., see Yhnell, E. (2) 149–161  
  
 Eberly, S., see Anderson, K.E. (4) 389–394  
 Edmondson, M., see Frich, J.C. (2) 207–213  
 Erdős, A., see Billes, V. (2) 133–147  
  
 Faull, K.F., see Chen, J.Y. (1) 65–81  
 Faull, R.L.M., see Geraerts, F.C.A. (3) 297–301  
 Felong, T.J., see Andrzejewski, K.L. (2) 199–206  
 Fisher, C.A., see Moorhouse, B. (1) 15–17  
 Fisher, F., see Philpott, A.L. (2) 175–183  
 Fox, J.A., see Berggren, K.L. (1) 53–63  
 Fox, J.H., see Berggren, K.L. (1) 53–63  
 Frich, J.C., D. Rae, R. Roxburgh, Z.H. Miedzybrodzka, M. Edmondson, E.B. Pope, L.V. Goodman, M.S. Haddad, J. Giuliano, E.C. Nelson, M. Guttman and M. Nance, Health Care Delivery Practices in Huntington's Disease Specialty Clinics: An International Survey (2) 207–213  
 Frich, J.C., see van Walsem, M.R. (3) 261–270  
  
 Garner, B., see Kreilau, F. (3) 285–296  
 Geraerts, F.C.A., R.G. Snell, R.L.M. Faull, L. Williams, J.C. Jacobsen and S.J. Reid, Comparison of Huntington's disease CAG Repeat Length Stability in Human Motor Cortex and Cingulate Gyrus (3) 297–301  
 Gilbert, P.E., see Corey-Bloom, J. (1) 91–96  
 Giltay, E.J., see Bouwens, J.A. (4) 369–377  
 Giltay, E.J., see Hubers, A.A.M. (2) 185–198  
 Giuliano, J., see Frich, J.C. (2) 207–213  
 Gluhm, S., see Corey-Bloom, J. (1) 91–96  
 Goodman, L.V., see Frich, J.C. (2) 207–213  
 Groves, M., see Anderson, K.E. (4) 389–394  
 Gulya, K., see Billes, V. (2) 133–147  
 Gulyás, B., see Billes, V. (2) 133–147  
 Guttman, M., see Frich, J.C. (2) 207–213  
 Gwin, J.T., see Andrzejewski, K.L. (2) 199–206  
  
 Haddad, M.S., see Frich, J.C. (2) 207–213  
 Hamming, A., see Hubers, A.A.M. (2) 185–198  
 Hannan, A.J., see Kreilau, F. (3) 285–296  
 Haque, A.S., see Corey-Bloom, J. (1) 91–96  
 Harris, D.A., see Andrzejewski, K.L. (2) 199–206  
 Hart, E.P., see Baake, V. (1) 83–90  
 Heguy, A., see Culver, B.P. (1) 39–51  
 Herndon, A., see Corey-Bloom, J. (1) 91–96  
 Hersch, S., see Chopra, V. (4) 347–355  
 Hotzi, B., see Billes, V. (2) 133–147  
 Howe, E.I., see van Walsem, M.R. (3) 261–270  
 Hubers, A.A.M., A. Hamming, E.J. Giltay, M. von Faber, R.A.C. Roos, R.C. van der Mast and E. van Duijn, Suicidality in Huntington's Disease: A Qualitative Study on Coping Styles and Support Strategies (2) 185–198  
 Hwang, L., see Chen, J.Y. (1) 65–81  
  
 Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity (2) 99–131  
 Iuliano, M., see Vodicka, P. (2) 163–174  
 Iuliano, M., see Vodicka, P. (3) 249–260  
  
 Jacobsen, J.C., see Geraerts, F.C.A. (3) 297–301  
 Jenner, A.M., see Kreilau, F. (3) 285–296  
 Jung, M.E., see Chen, J.Y. (1) 65–81  
  
 Kayson, E., see Anderson, K.E. (4) 389–394  
 Kazantsev, A.G., see Chopra, V. (4) 347–355  
 Keeler, A.M., E. Sapp, K. Chase, E. Sottosanti, E. Danielson, E. Pfister, L. Stoica, M. DiFiglia, N. Aronin and M. Sena-Esteves, Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice (3) 239–248  
 Kegel-Gleason, K.B., see Tousley, A. (2) 99–131  
 Kegel-Gleason, K.B., see Vodicka, P. (2) 163–174  
 Kegel-Gleason, K.B., see Vodicka, P. (3) 249–260  
 Kennington, L.A., see Liu, W. (1) 33–38  
 Khanna, P., see Chopra, V. (4) 347–355  
 Kogan, J., see Simpson, J.A. (4) 395–403  
 Komlós, M., see Billes, V. (2) 133–147  
 Kovács, T., see Billes, V. (2) 133–147

- Kreilaus, F., A.S. Spiro, A.J. Hannan, B. Garner and A.M. Jenner, Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice (3) 285–296
- Kuhn, R., see Chopra, V. (4) 347–355
- Kumar, A. and R.R. Ratan, Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly (3) 217–237
- Legradi, A., see Billes, V. (2) 133–147
- Levine, M.S., see Chen, J.Y. (1) 65–81
- Little, M.A., see Andrzejewski, K.L. (2) 199–206
- Liu, W., E.L. Pfister, L.A. Kennington, K.O. Chase, C. Mueller, M. DiFiglia and N. Aronin, Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon? (1) 33–38
- Long, J.D., see Downing, N.R. (4) 357–368
- Lourens, S., see Downing, N.R. (4) 357–368
- Lovecky, D., see Simpson, J.A. (4) 395–403
- Lu, B., see Vodicka, P. (2) 163–174
- Lu, Z., see Berggren, K.L. (1) 53–63
- Ma, B., see Culver, B.P. (1) 39–51
- MacDonald, M., see Braisch, U. (4) 379–387
- Manz ger, A., see Billes, V. (2) 133–147
- Marder, K., see Anderson, K.E. (4) 389–394
- Martinez-Horta, S., see Braisch, U. (4) 379–387
- Miedzybrodzka, Z.H., see Frich, J.C. (2) 207–213
- Moorhouse, B. and C.A. Fisher, Long-Term use of Modified Diets in Huntington's Disease: A Descriptive Clinical Practice Analysis on Improving Dietary Enjoyment (1) 15–17
- Morton, A.J., see Sawiak, S.J. (3) 271–283
- Morton, A.J., see Skillings, E.A. (1) 19–32
- Mueller, C., see Liu, W. (1) 33–38
- Nance, M., see Frich, J.C. (2) 207–213
- Nelson, E.C., see Frich, J.C. (2) 207–213
- Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington's Disease Mice (1) 53–63
- Orth, M., see Braisch, U. (4) 379–387
- Osmand, A.P., T.J. Bichell, A.B. Bowman and G.P. Bates, Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease (4) 343–346
- P d r, Z., see Billes, V. (2) 133–147
- Paganetti, P., see Chopra, V. (4) 347–355
- Park, S., see Corey-Bloom, J. (1) 91–96
- Paulsen, J.S., see Downing, N.R. (4) 357–368
- Pfister, E., see Keeler, A.M. (3) 239–248
- Pfister, E.L., see Liu, W. (1) 33–38
- Philpott, A.L., S.C. Andrews, M. Staios, A. Churchyard and F. Fisher, Emotion Evaluation and Social Inference Impairments in Huntington's Disease (2) 175–183
- Pope, E.B., see Frich, J.C. (2) 207–213
- Quinti, L., see Chopra, V. (4) 347–355
- Rae, D., see Frich, J.C. (2) 207–213
- Rangel-Barajas, C. and G.V. Rebec, Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation (4) 303–331
- Ratan, R.R., see Kumar, A. (3) 217–237
- Rebec, G.V., see Rangel-Barajas, C. (4) 303–331
- Reid, S.J., see Geraerts, F.C.A. (3) 297–301
- Reilmann, R., see Andrzejewski, K.L. (2) 199–206
- Roos, R.A.C., see Baake, V. (1) 83–90
- Roos, R.A.C., see Bouwens, J.A. (4) 369–377
- Roos, R.A.C., see Hubers, A.A.M. (2) 185–198
- Roxburgh, R., see Frich, J.C. (2) 207–213
- Sapp, E., see Keeler, A.M. (3) 239–248
- Sapp, E., see Vodicka, P. (2) 163–174
- Sapp, E., see Vodicka, P. (3) 249–260
- Sawiak, S.J., N.I. Wood and A.J. Morton, Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by *In Vivo* Magnetic Resonance Imaging and Spectroscopy (3) 271–283
- Sena-Esteves, M., see Keeler, A.M. (3) 239–248
- Sena-Esteves, M., see Vodicka, P. (2) 163–174
- Sena-Esteves, M., see Vodicka, P. (3) 249–260
- Shoulson, I., see Anderson, K.E. (4) 389–394
- Simpson, J.A., D. Lovecky, J. Kogan, L.A. Vetter and G.J. Yohrling, Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs (4) 395–403
- Skillings, E.A. and A.J. Morton, Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease (1) 19–32
- Snell, R.G., see Geraerts, F.C.A. (3) 297–301
- Sottosanti, E., see Keeler, A.M. (3) 239–248
- Spiro, A.S., see Kreilaus, F. (3) 285–296

- Staios, M., see Philpott, A.L. (2) 175–183  
Stamler, D., see Andrzejewski, K.L. (2) 199–206  
Stoica, L., see Keeler, A.M. (3) 239–248
- Tagscherer, K., see Billes, V. (2) 133–147  
Tanese, N., see Culver, B.P. (1) 39–51  
Tarnóci, A., see Billes, V. (2) 133–147  
Tousley, A. and K.B. Kegel-Gleason  
Tousley, A., see Vodicka, P. (3) 249–260  
Tran, C., see Chen, J.Y. (1) 65–81
- Valentine, D.T., see Vodicka, P. (2) 163–174  
Valentine, D.T., see Vodicka, P. (3) 249–260  
van der Mast, R.C., see Bouwens, J.A. (4) 369–377  
van der Mast, R.C., see Hubers, A.A.M. (2) 185–198  
van Duijn, E., see Bouwens, J.A. (4) 369–377  
van Duijn, E., see Hubers, A.A.M. (2) 185–198  
van Walsem, M.R., E.I. Howe, J.C. Frich and N. Andelic, Assistive Technology for Cognition and Health-related Quality of Life in Huntington's Disease (3) 261–270  
Vellai, T., see Billes, V. (2) 133–147  
Vetter, L.A., see Simpson, J.A. (4) 395–403  
Vodicka, P., K. Chase, M. Iuliano, A. Tousley, D.T. Valentine, E. Sapp, K.B. Kegel-Gleason, M. Sena-Esteves, N. Aronin and M. DiFiglia, Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HD<sup>Q175/Q7</sup> Mice (3) 249–260  
Vodicka, P., K. Chase, M. Iuliano, D.T. Valentine, E. Sapp, B. Lu, K.B. Kegel-Gleason, M. Sena-Esteves, N. Aronin and M. DiFiglia, Effects of Exogenous NUB1 Expression in the Striatum of HD<sup>Q175/Q7</sup> Mice (2) 163–174  
von Faber, M., see Hubers, A.A.M. (2) 185–198
- Waldvogel, H.J., see D'Souza, G.X. (4) 333–342  
Wild, E.J., see Byrne, L.M. (1) 1–13  
Williams, L., see Geraerts, F.C.A. (3) 297–301  
Wong, C., see Andrzejewski, K.L. (2) 199–206  
Wood, N.I., see Sawiak, S.J. (3) 271–283
- Yhnell, E., S.B. Dunnett and S.P. Brooks, A Longitudinal Motor Characterisation of the *Hdh*<sup>Q111</sup> Mouse Model of Huntington's Disease (2) 149–161  
Yohrling, G.J., see Simpson, J.A. (4) 395–403  
Young, A.B., see Anderson, K.E. (4) 389–394  
Young, A.B., see Chopra, V. (4) 347–355  
Yu, M.S., see Culver, B.P. (1) 39–51